Dexamethasone for Cardiac Surgery trial (DECS-II): Rationale and a novel, practice preference-randomized consent design

American Heart Journal

Volumn 204, Issue , 2018, Pages 52-57

  Myles, Paul S ^a,b   Dieleman, Jan M ^c   Forbes, Andrew ^b   Heritier, Stephane ^b   Smith, Julian A ^b,d  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d SOUTHERN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; PLACEBO; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID;

ARTICLE; BLOOD TRANSFUSION; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CLINICAL PRACTICE; DRUG MEGADOSE; DRUG SCREENING; FOLLOW UP; HEART SURGERY; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; PRIORITY JOURNAL; STEROID THERAPY; SURGICAL PATIENT; ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CARDIAC SURGICAL PROCEDURES; DEXAMETHASONE; FEMALE; GLUCOCORTICOIDS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATIONS; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 85050880645     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2018.06.008     Document Type: Article

References (42)

1. Asimakopoulos, G., Systemic inflammation and cardiac surgery: an update. Perfusion 16:5 (2001), 353–360.
2. Trop, S., Marshall, J.C., Mazer, C.D., et al. Perioperative cardiovascular system failure in South Asians undergoing cardiopulmonary bypass is associated with prolonged inflammation and increased Toll-like receptor signaling in inflammatory monocytes. J Surg Res 187:1 (2014), 43–52.
3. MacCallum, N.S., Finney, S.J., Gordon, S.E., et al. Modified criteria for the systemic inflammatory response syndrome improves their utility following cardiac surgery. Chest 145:6 (2014), 1197–1203.
4. Chaney, M.A., Corticosteroids and cardiopulmonary bypass: a review of clinical investigations. Chest 121:3 (2002), 921–931.
5. Dieleman, J.M., van Paassen, J., van Dijk, D., et al. Prophylactic corticosteroids for cardiopulmonary bypass in adults. Cochrane Database Syst Rev(5), 2011, CD005566.
6. Dieleman, J.M., Nierich, A.P., Rosseel, P.M., et al. Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial. JAMA 308:17 (2012), 1761–1767.
7. Whitlock, R.P., Devereaux, P.J., Teoh, K.H., et al. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet 386:10000 (2015), 1243–1253.
8. Jacob, K.A., Leaf, D.E., Dieleman, J.M., et al. Intraoperative High-Dose Dexamethasone and Severe AKI after Cardiac Surgery. J Am Soc Nephrol 26:12 (2015), 2947–2951.
9. Whitlock, R.P., Young, E., Noora, J., et al. Pulse low dose steroids attenuate post-cardiopulmonary bypass SIRS; SIRS I. J Surg Res 132:2 (2006), 188–194.
10. Zelen, M., A new design for randomized clinical trials. N Engl J Med 300:22 (1979), 1242–1245.
11. Hadorn, D., Wilson, N., Edwards, R., et al. How to substantially increase recruitment in cancer trials in New Zealand. N Z Med J 126:1381 (2013), 57–68.
12. Schellings, R., Kessels, A.G., ter Riet, G., et al. Randomized consent designs in randomized controlled trials: systematic literature search. Contemp Clin Trials 27:4 (2006), 320–332.
13. Matts, J., McHugh, R., Randomization and efficiency in Zelen's single-consent design. Biometrics 43:4 (1987), 885–894.
14. Hawkins, J.S., The ethics of Zelen consent. J Thromb Haemost 2:6 (2004), 882–883.
15. Sheehan, M., Can broad consent be informed consent?. Public Health Ethics 4:3 (2011), 226–235.
16. Ariti, C.A., Cleland, J.G., Pocock, S.J., et al. Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J 162:5 (2011), 900–906.
17. Wasywich, C.A., Gamble, G.D., Whalley, G.A., et al. Understanding changing patterns of survival and hospitalization for heart failure over two decades in New Zealand: utility of ‘days alive and out of hospital’ from epidemiological data. Eur J Heart Fail 12:5 (2010), 462–468.
18. Singer, M., Deutschman, C.S., Seymour, C.W., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:8 (2016), 801–810.
19. Thygesen, K., Alpert, J.S., Jaffe, A.S., et al. Third universal definition of myocardial infarction. Circulation 126:16 (2012), 2020–2035.
20. Mehta, R.L., Kellum, J.A., Shah, S.V., et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care, 11(2), 2007, R31.
21. Shulman, M.A., Myles, P.S., Chan, M.T., et al. Measurement of disability-free survival after surgery. Anesthesiology 122:3 (2015), 524–536.
22. Organisation WH, World Report on Disability. http://wwwwhoint/disabilities/world_report/2011/reportpdf Technical appendix C, 2011, 287–294.
23. Kok, L., Hillegers, M.H., Veldhuijzen, D.S., et al. The effect of dexamethasone on symptoms of posttraumatic stress disorder and depression after cardiac surgery and intensive care admission: longitudinal follow-up of a randomized controlled trial. Crit Care Med 44:3 (2016), 512–520.
24. Dvirnik, N., Devereaux, P., Lamy, A., et al. Steroids in cardiac surgery: a systematic review and meta-analysis. Br J Anaesth 120:4 (2018), 657–667 [submitted].
25. Myles, P.S., Smith, J.A., Painter, T., Aspirin before Coronary Artery Surgery. N Engl J Med 375:1 (2016), 91–92.
26. Koenker, R., Bassett, G., Regression quantiles. Econometrica 46 (1978), 33–50.
27. Reith, C., Landray, M., Devereaux, P.J., et al. Randomized clinical trials–removing unnecessary obstacles. N Engl J Med 369:11 (2013), 1061–1065.
28. Jackson, N., Atar, D., Borentain, M., et al. Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. Eur Heart J 37:9 (2016), 747–754.
29. Macleod, M.R., Michie, S., Roberts, I., et al. Biomedical research: increasing value, reducing waste. Lancet 383:9912 (2014), 101–104.
30. Berry, S.M., Connor, J.T., Lewis, R.J., The platform trial: an efficient strategy for evaluating multiple treatments. JAMA 313:16 (2015), 1619–1620.
31. Brown, C.H., Ten Have, T.R., Jo, B., et al. Adaptive designs for randomized trials in public health. Annu Rev Public Health 30 (2009), 1–25.
32. Woertman, W., de Hoop, E., Moerbeek, M., et al. Stepped wedge designs could reduce the required sample size in cluster randomized trials. J Clin Epidemiol 66:7 (2013), 752–758.
33. Relton, C., Torgerson, D., O'Cathain, A., et al. Rethinking pragmatic randomised controlled trials: introducing the “cohort multiple randomised controlled trial” design. BMJ, 340, 2010, c1066.
34. Ford, I., Norrie, J., Pragmatic Trials. N Engl J Med 375:5 (2016), 454–463.
35. Calvo, G., McMurray, J.J., Granger, C.B., et al. Large streamlined trials in cardiovascular disease. Eur Heart J 35:9 (2014), 544–548.
36. Wilcox, N., McNeil, J.J., Clinical quality registries have the potential to drive improvements in the appropriateness of care. Med J Aust 205:10 (2016), S27–s29.
37. Sugarman, J., Califf, R.M., Ethics and regulatory complexities for pragmatic clinical trials. JAMA 311:23 (2014), 2381–2382.
38. Godlee, F., More research is needed — but what type?. BMJ, 341, 2010, c4662.
39. Faden, R.R., Beauchamp, T.L., Kass, N.E., Informed consent for comparative effectiveness trials. N Engl J Med 370:20 (2014), 1959–1960.
40. Cowie, M.R., Blomster, J.I., Curtis, L.H., et al. Electronic health records to facilitate clinical research. Clin Res Cardiol 106:1 (2017), 1–9.
41. Glasser, S.P., Salas, M., Delzell, E., Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems. J Clin Pharmacol 47:9 (2007), 1074–1086.
42. Zhang, X., Zhang, Y., Ye, X., et al. Overview of phase IV clinical trials for postmarket drug safety surveillance: a status report from the ClinicalTrials.gov registry. BMJ Open, 6(11), 2016, e010643.